IL140796A0 - An autologous anti-cancer vaccine - Google Patents

An autologous anti-cancer vaccine

Info

Publication number
IL140796A0
IL140796A0 IL14079601A IL14079601A IL140796A0 IL 140796 A0 IL140796 A0 IL 140796A0 IL 14079601 A IL14079601 A IL 14079601A IL 14079601 A IL14079601 A IL 14079601A IL 140796 A0 IL140796 A0 IL 140796A0
Authority
IL
Israel
Prior art keywords
cancer vaccine
autologous anti
autologous
vaccine
cancer
Prior art date
Application number
IL14079601A
Original Assignee
Hadasit Med Res Service
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Med Res Service filed Critical Hadasit Med Res Service
Priority to IL14079601A priority Critical patent/IL140796A0/en
Priority to AU2002219485A priority patent/AU2002219485A1/en
Priority to PCT/IL2002/000012 priority patent/WO2002053176A2/en
Publication of IL140796A0 publication Critical patent/IL140796A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/056—Immunostimulating oligonucleotides, e.g. CpG
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
IL14079601A 2001-01-08 2001-01-08 An autologous anti-cancer vaccine IL140796A0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
IL14079601A IL140796A0 (en) 2001-01-08 2001-01-08 An autologous anti-cancer vaccine
AU2002219485A AU2002219485A1 (en) 2001-01-08 2002-01-06 An autologous anti-cancer vaccine
PCT/IL2002/000012 WO2002053176A2 (en) 2001-01-08 2002-01-06 An autologous anti-cancer vaccine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL14079601A IL140796A0 (en) 2001-01-08 2001-01-08 An autologous anti-cancer vaccine

Publications (1)

Publication Number Publication Date
IL140796A0 true IL140796A0 (en) 2002-02-10

Family

ID=11075015

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14079601A IL140796A0 (en) 2001-01-08 2001-01-08 An autologous anti-cancer vaccine

Country Status (3)

Country Link
AU (1) AU2002219485A1 (en)
IL (1) IL140796A0 (en)
WO (1) WO2002053176A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008121461A2 (en) * 2007-02-26 2008-10-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Vaccine for activating helper function of cd8+ tcells
EA009325B1 (en) 2007-03-07 2007-12-28 Петр Генриевич ЛОХОВ Antitumor vaccine, method for preparing thereof and method for using antitumor immunotherapy
AR060424A1 (en) * 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec CELLULAR LINES, COMPOSITIONS FOR THE TREATMENT OF MELANOMS THAT UNDERSTAND PROCEDURES TO PREPARE COMPOSITIONS AND TREATMENT METHODS
CL2007002825A1 (en) 2007-09-28 2008-05-30 Univ De Chile Oncobiomed METHOD FOR GENERATING VACCINES THAT STIMULATE THE IMMUNE SYSTEM THAT INCLUDES INDUCTING PERIPHERAL BLOOD MONONUCLEAR CELLS TO BE DIFFERENTIATED FROM APC, THEN, SEPARATE SUCH APC AND MIX THEM WITH ADJUVANTS; EXTRACT OF TUMOR CELLS; AND COMP
WO2012156969A1 (en) * 2011-05-17 2012-11-22 Hadasit Medical Research Services And Development Ltd. Allogeneic tumor cell vaccination
NZ628292A (en) * 2012-02-02 2016-09-30 Neostem Oncology Llc Pluripotent germ layer origin antigen presenting cancer vaccine
CN103372203B (en) * 2012-04-17 2015-05-06 国家纳米科学中心 Antigen composition, preparation method and application of antigen composition and tumour vaccine
CN103800896A (en) * 2012-11-15 2014-05-21 厦门鹭佳生物科技有限公司 Preparation method and application of autologous tumor vaccine
CN106794230A (en) * 2014-03-17 2017-05-31 德意志联邦共和国代表主席罗伯特·科赫研究所 Medicine for inducing or extending the method for the cytotoxic immune response of cell
WO2016201658A1 (en) * 2015-06-17 2016-12-22 深圳市达科为生物工程有限公司 Method for preparing tumor specific ctls

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1991097A (en) * 1996-03-15 1997-10-01 Immunotherapy, Inc. Dialdehydes as immunostimulatory adjuvants and cross-linkers for producing immunogenic preparations and generating pressure and cross-linked treated cells for enhancing and augmenting the immune response against cancers, tumors and pathogenic diseases
US6428782B1 (en) * 1997-05-23 2002-08-06 Hadasit Medical Research Services And Development Ltd. Non-myeloablative tolerogenic treatment

Also Published As

Publication number Publication date
WO2002053176A2 (en) 2002-07-11
WO2002053176A3 (en) 2002-12-19
AU2002219485A1 (en) 2002-07-16

Similar Documents

Publication Publication Date Title
IL227966A0 (en) Vaccine composition
EP1528937A4 (en) Nanoemulsion vaccines
IL159964A0 (en) Beta-amyloid-analogue-t-cell epitop vaccine
GB0103170D0 (en) Vaccine composition
GB0103171D0 (en) Vaccine composition
HUP0402471A3 (en) Vaccine
GB0407935D0 (en) Vaccine
HUP0402259A3 (en) Vaccines
GB0306611D0 (en) Novel vaccine
IL157498A0 (en) Vaccine
EP1423141A4 (en) Vaccine
HUP0303942A3 (en) Novel vaccine composition
GB0121171D0 (en) Vaccine
EP1660636A4 (en) Anti-cancer vaccines
IL140796A0 (en) An autologous anti-cancer vaccine
GB0105238D0 (en) Vaccines
GB0308691D0 (en) Vaccine preparations
GB0104538D0 (en) Novel Vaccine
GB0104542D0 (en) Novel vaccine
GB0107511D0 (en) Novel vaccine
GB0115496D0 (en) Vaccine
GB0124137D0 (en) Vaccine
GB0128312D0 (en) Vaccine
GB0130823D0 (en) Vaccine
GB0106589D0 (en) Vaccine